56 related articles for article (PubMed ID: 19608275)
1. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.
Yan M; Wang H; Wei R; Li W
Arch Pharm Res; 2024 Mar; 47(3):249-271. PubMed ID: 38147202
[TBL] [Abstract][Full Text] [Related]
4. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38
Asano T; Narazaki H; Fujita A
Pharmacol Res Perspect; 2017 Feb; 5(1):e00285. PubMed ID: 28596837
[TBL] [Abstract][Full Text] [Related]
6. Mitigating potential of Melissa officinale against As
Dwivedi S; Kumar M; Trivedi SP
Environ Monit Assess; 2017 Jul; 189(7):306. PubMed ID: 28573351
[TBL] [Abstract][Full Text] [Related]
7. [miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway].
Zhang Y; Shen XJ; Wu XH; Cong H; Ni HB; Ju SQ; Su JY
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):987-992. PubMed ID: 27995886
[TBL] [Abstract][Full Text] [Related]
8. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
9. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
[TBL] [Abstract][Full Text] [Related]
10. Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.
Alsadeq A; Strube S; Krause S; Carlet M; Jeremias I; Vokuhl C; Loges S; Aguirre-Ghiso JA; Trauzold A; Cario G; Stanulla M; Schrappe M; Schewe DM
Leukemia; 2015 Dec; 29(12):2307-16. PubMed ID: 26104660
[TBL] [Abstract][Full Text] [Related]
11. The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma.
Li X; Sun WJ
Onco Targets Ther; 2015; 8():775-81. PubMed ID: 25914547
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.
He X; Yang K; Chen P; Liu B; Zhang Y; Wang F; Guo Z; Liu X; Lou J; Chen H
Onco Targets Ther; 2014; 7():1593-9. PubMed ID: 25246802
[TBL] [Abstract][Full Text] [Related]
13. p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.
Grossi V; Peserico A; Tezil T; Simone C
World J Gastroenterol; 2014 Aug; 20(29):9744-58. PubMed ID: 25110412
[TBL] [Abstract][Full Text] [Related]
14. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.
Wen J; Tao W; Kuiatse I; Lin P; Feng Y; Jones RJ; Orlowski RZ; Zu Y
Int J Cancer; 2015 Mar; 136(5):991-1002. PubMed ID: 25042852
[TBL] [Abstract][Full Text] [Related]
15. High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.
Wen J; Li H; Tao W; Savoldo B; Foglesong JA; King LC; Zu Y; Chang CC
Br J Haematol; 2014 Sep; 166(5):711-9. PubMed ID: 24889268
[TBL] [Abstract][Full Text] [Related]
16. Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach.
Peng H; Peng T; Wen J; Engler DA; Matsunami RK; Su J; Zhang L; Chang CC; Zhou X
Bioinformatics; 2014 Jul; 30(13):1899-907. PubMed ID: 24618474
[TBL] [Abstract][Full Text] [Related]
17. Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Su J; Zhang L; Zhang W; Choi DS; Wen J; Jiang B; Chang CC; Zhou X
PLoS One; 2014; 9(1):e85059. PubMed ID: 24475036
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway.
Hu J; Huang X; Hong X; Lu Q; Zhu X
Cancer Cell Int; 2013 Mar; 13(1):25. PubMed ID: 23497375
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.
Doudican NA; Wen SY; Mazumder A; Orlow SJ
Oncol Rep; 2012 Nov; 28(5):1851-8. PubMed ID: 22922937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
